Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease.

Richard, Edo; den Brok, Melina G H E; van Gool, Willem A

Richard, Edo; den Brok, Melina G H E; van Gool, Willem A.

Afiliação

Richard E; Department of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behaviour, Nijmegen, the Netherlands.
den Brok MGHE; Department of Public and Occupational Health, Amsterdam University Medical Centre, AMC, University of Amsterdam, the Netherlands.
van Gool WA; Department of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behaviour, Nijmegen, the Netherlands.

Alzheimers Dement ; 17(6): 1051-1055, 2021 06.

Article em En | MEDLINE | ID: mdl-34057297

Assuntos

Doença de Alzheimer/tratamento farmacológico; Teorema de Bayes; Imunoterapia; Ensaios Clínicos Controlados Aleatórios como Assunto; Peptídeos beta-Amiloides/imunologia; Humanos

Palavras-chave

Alzheimer's disease; Bayesian analysis; anti-amyloid beta immunotherapy; dementia; evidence of absence; meta-analysis; randomized controlled trial

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto / Teorema de Bayes / Doença de Alzheimer / Imunoterapia Tipo de estudo: Clinical_trials / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google